Pershing Square Valeant Pharma (VRX) Conf. Call Up and Running after Technical Difficulties
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Pershing Square Valeant Pharma (VRX) Conf. Call Up and Running after Technical Difficulties
October 30, 2015 12:57 PM EDT
The bull-bear battle in beaten up and highly-questioned Valeant Pharma (NYSE: VRX) took center stage again today. Bill Ackman from Pershing Square on the bull side and Andrew Left from Citron Research on the bear side. Currently the bears are winning and the stock is down another 10% today and again below the $100 level.
This morning the company announced that it is severing all ties with Philidor Rx and Philidor has informed Valeant that it will shut down operations as soon as possible. Valeant's controversial... More
October 30, 2015 10:14 AM EDT
On the Valeant Pharma (NYSE: VRX) call, Bill Ackman said Valeant worth $180-$240 and worth $262-$350 longer term (2020).
...
More
October 30, 2015 9:26 AM EDT
On its Valeant Pharma (NYSE: VRX) call, Bill Ackman suggests Amazon.com (NASDAQ: AMZN) should distribute drugs. He said the specialty pharmacy model is future, cutting out wholesalers.
...
More
October 30, 2015 8:53 AM EDT
Down 7.6% currently, Valeant Pharma (NYSE: VRX) is on watch ahead of Bill Ackman's conference call, which is starting at 9:00AM ET.
During the call, Bill Ackman and other members of the Pershing Square investment team will address questions from investors... More
